The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)
The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)
复制标题
DOI：
10.1016/j.jinf.2010.08.010
复制
发表时间：
2010-12-01
影响因子：
28.2
通讯作者：
Jones, Ronald N.
中科院分区：
文献类型：
--
作者：
Farrell, David J.;Castanheira, Mariana;Jones, Ronald N.
目的：索利霉素（原CEM-101）是一种新型氟酮内酯，对其他MLSB-酮内酯药物敏感或耐药的细菌病原体具有强效活性。本研究的目的是评估索利霉素和对照抗菌剂对2009年在美国（美国）和欧洲收集的大量和各种当代临床细菌病原体的活性。方法：2009年期间，从位于美国的52个医疗中心收集了总计10，670株非重复临床分离株（27个中心; 6228株分离株）和欧洲（25个中心; 4442株分离株）。使用CLSI参考方法进行药敏试验和解释。在1363株肺炎链球菌分离株中，99.9%的菌株显示索利霉素MIC值为4 mg/L）对甲氧西林敏感菌株的活性更高（MIC 50，0.06 mg/L和MIC 90，0.06 mg/L）与甲氧西林耐药分离株（MIC 50，0.06 mg/L和MIC 90，>4 mg/L）相比。索利霉素对所有757种β-溶血性链球菌都非常有效（MIC 50，
Objectives: Solithromycin (formerly CEM-101) is a novel fluoroketolide with potent activity against bacterial pathogens that are susceptible or resistant to other MLSB-ketolide agents. The objective of this study was to assess the activity of solithromycin and comparator antimicrobials against a large number and variety of contemporary clinical bacterial pathogens collected in the United States (USA) and Europe during 2009.Method: During 2009, a total of 10,670 non-duplicated clinical isolates were collected from 52 medical centers located in the USA (27 centers; 6228 isolates) and Europe (25 centers; 4442 isolates). Susceptibility testing and interpretation were performed using CLSI reference methods.Results: Among 1363 Streptococcus pneumoniae isolates, 99.9% of the strains displayed solithromycin MIC values at 4 mg/L) activity was greater against methicillin-susceptible isolates (MIC50, 0.06 mg/L and MIC90, 0.06 mg/L) compared to methicillin-resistant isolates (MIC50, 0.06 mg/L and MIC90, >4 mg/L). Solithromycin was very active against all 757 beta-haemolytic streptococci (MIC50,